Ramoplanin

N/A

Report date: 2022/01/14 13:23:58
NME

Base Information

Drug NameRamoplanin
Drug Alias Name蓝莫拉宁ramoplanina雷冒拉宁ramoplaninumramoplanine +[10] 
ClassificationSmall molecules > Synthetic peptideSmall molecules > Heterocyclic drugs > Antibiotics
Mechanisms of ActionCell wall inhibitors
TargetsNot applicable
Therapy Area/IndicationsDiarrheaCarcinoma, Non-Small-Cell LungEsophageal Neoplasms +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusDiscontinued (Phase 3 Clinical)
Highest Status in ChinaN/A
Originator CompaniesPfizer Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesPfizer IncNational Cancer InstituteOlogy Bioservices Inc
Active IndicationsN/A
Inactive IndicationsDiarrheaCarcinoma, Non-Small-Cell LungEsophageal Neoplasms +[6] 

Other Information

ATC CodeN/A
Related LinksWikipediaDrugBankKEGG